<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002633'>Vasculitis</z:hpo> is accepted to be the basis of <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) which is a multisystem disease, and the <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>(AA) metabolites acting as balancing mediators in the organism are accepted to be responsible for the <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined the <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> (<z:chebi fb="0" ids="15551">PGE2</z:chebi>) and <z:chebi fb="0" ids="16978">leukotriene C4</z:chebi> (<z:chebi fb="0" ids="16978">LTC4</z:chebi>) levels of the patients with BD before and after <z:chebi fb="0" ids="23359">colchicine</z:chebi> therapy </plain></SENT>
<SENT sid="2" pm="."><plain>We found a statistical decrease in the <z:chebi fb="0" ids="15551">PGE2</z:chebi> and <z:chebi fb="0" ids="16978">LTC4</z:chebi> levels after <z:chebi fb="0" ids="23359">colchicine</z:chebi> therapy compared to the previous levels, concluding that <z:chebi fb="0" ids="23359">colchicine</z:chebi> inhibits the <z:mp ids='MP_0001845'>inflammation</z:mp> and the polymorphonuclear leukocyte (PML) chemotaxis by inhibiting the cyclooxygenase and lipoxygenase pathways </plain></SENT>
</text></document>